Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

被引:8
作者
Chamouni, P
Tamion, F
Gueit, I
Girault, C
Lenain, P
Varin, R
Czernichow, P
机构
[1] CHU Rouen, Dept Epidemiol & Sante Publ, Unite Hemovigilance, F-76031 Rouen, France
[2] Univ Rouen, Hosp Charles Nicolle, Dept Epidemiol & Publ Hlth, Rouen, France
[3] Univ Rouen, Hosp Charles Nicolle, Intens Care Unit, Rouen, France
[4] Ctr Henri Becquerel, Dept Haematol, F-76038 Rouen, France
[5] Univ Rouen, Hosp Charles Nicolle, Dept Pharmacol, Rouen, France
关键词
Guillain-Barre syndrome; intravenous immunoglobulin; hemolytic anaemia; ABO blood-group system; INTRAVENOUS IMMUNE GLOBULIN; BONE-MARROW TRANSPLANT; HEMOLYTIC-ANEMIA; PLASMA-EXCHANGE; ERYTHROCYTE SEQUESTRATION; THERAPY; IVIG; AUTOANTIBODIES; MODULATION; MECHANISM;
D O I
10.1016/S1473-0502(03)00012-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Acute polyradiculoneuropathy or Guillain-Barre syndrome is a neurological disease which may present with severe forms which have a poor prognosis. The patient's management requires multidisciplinary specialised care. Morbidity has been reported to be significantly improved with initial therapy using high-dose intravenous immunoglobulin (IVIG). However, this therapy represent an immunological risk which has remained overlooked by clinicians in the majority of cases and is not clearly stated by the pharmaceutical companies. Therefore, the use of IVIG in the intensive care unit can cause some problems. Case report: A 32-year-old woman presented with clinical signs of Guillain-Barre syndrome. The patient received high-dose intravenous immunoglobulin (TEGELINE(R)). Nine days after beginning therapy, she presented with severe immunological hemolytic anaemia; the IVIG was suspected as the cause. The blood cell count returned to normal approximately two months after the onset of the hemolytic syndrome. Conclusion: Despite the effectiveness of IVIG therapy in the management of various diseases, intensive care clinicians should be aware of possible major adverse effects which make a careful assessment of the patient necessary before treatment. It may also be important to consider the patient's ABO blood group before initiating IVIG treatment, particularly in patients bearing A and/or B blood group antigens. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 40 条
[1]  
Annane D, 1997, ANN NEUROL, V41, P298
[2]  
[Anonymous], CONT NEUROLOGY SERIE
[3]   INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITIS - ITS ROLE IN PATHOGENESIS [J].
ASBURY, AK ;
ARNASON, BG ;
ADAMS, RD .
MEDICINE, 1969, 48 (03) :173-&
[4]   Insisting upon intravenous immunoglobulin therapy in polymiositis case after severe hemolytic anemia. [J].
Ballot-Brossier, C ;
Mortelecque, R ;
Sinègre, M ;
Marceau, A ;
Dauriat, G ;
Courtois, F .
TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2001, 8 (02) :94-99
[5]  
Ben Ghorbel I, 1998, SEM HOP PARIS, V74, P994
[6]   HEMOLYTIC-ANEMIA FOLLOWING INTRAVENOUS GAMMA-GLOBULIN ADMINISTRATION [J].
BROX, AG ;
COURNOYER, D ;
STERNBACH, M ;
SPURLL, G .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (03) :633-635
[7]  
BUSSEL A, 1993, ANN MED INTERNE, V144, P532
[8]   IMMUNE HEMOLYSIS, DISSEMINATED INTRAVASCULAR COAGULATION, AND SERUM SICKNESS AFTER LARGE DOSES OF IMMUNE GLOBULIN GIVEN INTRAVENOUSLY FOR KAWASAKI-DISEASE [J].
COMENZO, RL ;
MALACHOWSKI, ME ;
MEISSNER, HC ;
FULTON, DR ;
BERKMAN, EM .
JOURNAL OF PEDIATRICS, 1992, 120 (06) :926-928
[9]  
COPELAN EA, 1985, TRANSFUSION, V26, P410
[10]  
DIETRICH G, 1992, BLOOD, V79, P2946